Accelerating Development, Reducing Risk

1

Accelerating Development, Reducing Risk
2
Biopta Strategy

• A unique human tissue company
• CRO services providing human safety and efficacy
  data
• Tissue bank status with extensive UK network
• Only GLP-compliant human tissue-based CRO
• An innovative instrument developer
• Target emerging human tissue testing market
  (projected to exceed 350M by 2008)
• We identify compounds with the greatest
  likelihood of clinical success

Accelerating Development, Reducing Risk
3
Biopta History

• Founded in 2002 By Dr David Bunton Prof Chris
  Hillier as a spin out of Glasgow Caledonian
  University
• Raised circa 1.1M in two rounds of private
  investment
• Winner of
• John Logie Baird Award for Innovation (2000)
• Proof of Concept Award (2001)
• Smart Scotland (2002)
• Nexxus Innovation Award (2006)

4
Drug Discovery a war of attrition?
Merck Announces Voluntary Worldwide Withdrawal of
VIOXX WHITEHOUSE STATION, N.J., Sept. 30,
5
Bridging the Gaps in Drug Discovery

• more than half of the side effects from
  pharmaceuticals are avoidable. 
• 
  
  FDA

• it is only with intact tissue or whole animals
  that verifiable detailed biological activity can
  be assessed.
• 
  National Association for Biomedical Research

Bioptas human tissue services have played a
critical part in our compound selection and have
added considerable value to our lead compound
. our investors were reassured by the presence of
functional data on living human tissues CEO,
Biotech, Canada
6
Biopta Services
Biopta services
Discovery Optimisation
Phase I
Phase II
Phase III
Target Validation
Preclinical Evaluation
Proof of concept in man
Human safety
Clinical Biopsies
7
Answers delivered through Biopta services
instruments

• Are my animal tests predictive of the human
  responses?
• Which of my compounds is the most
  potent/efficacious?
• Does my compound produce adverse responses in
  humans?
• What is the mechanism of drug action in humans?
• Is the drug target selectively expressed in human
  tissues?

8
Examples of Biopta Services
9
Biopta PM-1 Automated testing of drug efficacy
safety in human tissues

• Automated drug delivery to tissues, with
  patented
• optical readout of changes in tissue
  dimensions
• Allows efficacy and safety studies in a range
  of
• tubular tissues
• Designed, developed, manufactured and launched
• for less than 1M
• Pipeline of instruments in development

10
Growth Innovation

• 100 growth in CRO revenue for 2007
• Presently negotiating worldwide exclusive
  distribution agreement for PM-1 system
• Launch of human cardiac assays in June 07
• Pipeline
• Development of first assays and instruments for
  the study of human blood-brain barrier
• Fluorescent imaging of isolated tissues exposed
  to drugs under physiological conditions

11
Why Biopta?

• Entrepreneurial - development of multiple new
  services that address key gaps in emerging market
  of human tissue testing
• Innovative - patented analysis of tissue
  dimensions provides rapid functional information
  on drug responses
• Unique - first GLP functional human tissue
  company
• Successful - 16 world-wide clients providing gt60
  repeat business with first client moving from
  concept to clinic in less than 30 months (average
  4-6 years)

Accelerating Development, Reducing Risk